FAMILY CASE OF MITRAL VALVE PROLAPSE — IMPACT OF INCREASED LEVEL OF TRANSFORMING  GROWTH FACTOR β

1. Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease-current management and future challenges. Lancet. 2016; 387 (10025): 1324-34. DOI: 10.1016/S01406736(16)00558-4.

2. Rizzo S, Basso C, Lazzarini E, et al. TGF-beta1 pathway activation and adherens junction molecular pattern in nonsyndromic mitral valve prolapse. Cardiovasc Pathol. 2015; 24 (6): 359-67. DOI: 10.1016/j.carpath.2015.07.009.

3. Geirsson A, Singh M, Ali R, et al. Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation. 2012; 126 (11 Suppl 1): S189-97. DOI: 10.1161/CIRCULATIONAHA.111.082610.

4. Lyu L, Wang H, Li B, et al. A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes. J Mol Cell Cardiol. 2015; 89: 268-79. DOI: 10.1016/j.yjmcc.2015.10.022.

5. Yu C, Jeremy R. Angiotensin, transforming growth factor β and aortic dilatation in Marfan syndrome: of mice and humans. IJC Heart & Vasculature. 2018; 18: 71-80. DOI: 10.1016/j.ijcha.2018.02.009.